Holen Sie sich die Stockscreener-App
48.31
0.96%
0.46
Vorhandelsmarkt:
48.35
0.04
+0.08%
Schlusskurs vom Vortag:
$47.85
Offen:
$48.43
24-Stunden-Volumen:
1.75M
Relative Volume:
0.67
Marktkapitalisierung:
$121.02B
Einnahmen:
$48.62B
Nettoeinkommen (Verlust:
$6.80B
KGV:
17.23
EPS:
2.8038
Netto-Cashflow:
$7.62B
1W Leistung:
+0.27%
1M Leistung:
-2.15%
6M Leistung:
+0.17%
1J Leistung:
-0.43%
1-Tages-Spanne:
$47.99
$48.55
1-Wochen-Bereich:
$47.55
$48.93
52-Wochen-Spanne:
$45.80
$60.12
Sanofi Adr Stock (SNY) Company Profile
Vergleichen Sie SNY mit anderen Aktien
| Aktien | Preis | Marktkapitalisierung | Umsatz | Nettogewinn | Free Cashflow | ENV |
|---|---|---|---|---|---|---|
SNY
Sanofi Adr
|
48.31 | 121.02B | 48.62B | 6.80B | 7.62B | 2.8038 |
|
LLY
Lilly Eli Co
|
779.53 | 724.64B | 49.00B | 11.11B | -1.27B | 12.29 |
|
JNJ
Johnson Johnson
|
152.75 | 376.43B | 89.33B | 21.81B | 18.57B | 8.99 |
|
NVO
Novo Nordisk Adr
|
69.02 | 352.49B | 43.59B | 15.04B | 10.74B | 3.3766 |
|
ABBV
Abbvie Inc
|
185.62 | 334.73B | 57.37B | 4.20B | 15.39B | 2.35 |
|
NVS
Novartis Ag Adr
|
121.01 | 234.21B | 53.22B | 12.86B | 14.85B | 6.39 |
Sanofi Adr Stock (SNY) Upgrades & Downgrades
| Datum | Aktion | Analytiker | Ratingänderung |
|---|---|---|---|
| 2025-04-15 | Eingeleitet | Exane BNP Paribas | Outperform |
| 2025-03-21 | Eingeleitet | Goldman | Neutral |
| 2025-01-30 | Hochstufung | Deutsche Bank | Sell → Hold |
| 2024-07-26 | Bestätigt | Argus | Buy |
| 2024-01-23 | Eingeleitet | Morgan Stanley | Equal-Weight |
| 2024-01-16 | Fortgesetzt | UBS | Buy |
| 2023-12-05 | Herabstufung | JP Morgan | Overweight → Neutral |
| 2023-10-30 | Herabstufung | Stifel | Buy → Hold |
| 2023-09-06 | Hochstufung | Berenberg | Hold → Buy |
| 2023-07-14 | Eingeleitet | HSBC Securities | Buy |
| 2023-04-28 | Herabstufung | Deutsche Bank | Hold → Sell |
| 2023-03-27 | Hochstufung | Barclays | Equal Weight → Overweight |
| 2022-12-13 | Fortgesetzt | Morgan Stanley | Overweight |
| 2022-08-12 | Hochstufung | Deutsche Bank | Sell → Hold |
| 2022-08-09 | Herabstufung | UBS | Buy → Neutral |
| 2022-05-23 | Eingeleitet | SVB Leerink | Outperform |
| 2021-09-27 | Hochstufung | SVB Leerink | Mkt Perform → Outperform |
| 2021-01-15 | Eingeleitet | Deutsche Bank | Sell |
| 2020-09-29 | Eingeleitet | Berenberg | Hold |
| 2020-03-17 | Hochstufung | Barclays | Underweight → Equal Weight |
| 2020-03-11 | Hochstufung | Goldman | Neutral → Buy |
| 2020-02-11 | Eingeleitet | SVB Leerink | Mkt Perform |
| 2020-01-06 | Hochstufung | JP Morgan | Neutral → Overweight |
| 2019-09-23 | Hochstufung | Guggenheim | Neutral → Buy |
| 2019-09-20 | Hochstufung | Morgan Stanley | Equal-Weight → Overweight |
| 2019-09-03 | Eingeleitet | Bernstein | Outperform |
| 2019-08-14 | Hochstufung | UBS | Neutral → Buy |
| 2018-12-11 | Hochstufung | Jefferies | Hold → Buy |
| 2018-11-01 | Hochstufung | Barclays | Underweight → Equal Weight |
| 2018-10-09 | Eingeleitet | Guggenheim | Neutral |
| 2018-09-10 | Hochstufung | BofA/Merrill | Neutral → Buy |
| 2018-08-10 | Hochstufung | Citigroup | Neutral → Buy |
| 2018-03-23 | Hochstufung | Liberum | Hold → Buy |
| 2018-01-23 | Herabstufung | Barclays | Equal Weight → Underweight |
| 2017-12-06 | Herabstufung | BofA/Merrill | Buy → Neutral |
| 2017-12-01 | Herabstufung | Morgan Stanley | Overweight → Underweight |
| 2017-11-15 | Hochstufung | Barclays | Underweight → Equal Weight |
| 2017-08-30 | Hochstufung | HSBC Securities | Reduce → Hold |
Alle ansehen
Sanofi Adr Aktie (SNY) Neueste Nachrichten
INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of SanofiSNY - FinancialContent
Communiqué : Dupixent a démontré sa supériorité par rapport au Xolair dans la rhinosinusite chronique avec polypes nasaux chez des patients atteints d’asthme coexistant dans la toute 1ere étude respiratoire de ph4 en comparaison directe … - GlobeNewswire Inc.
SNY’s 2023 Market Dance: Up 3.92% – Time to Invest? - investchronicle.com
Sanofi: Information concerning the total number of voting rights and shares - GlobeNewswire Inc.
Weekly Stock Grader Analysis: Upgrades & Downgrades on Top Blue-Chip Stocks - InvestorPlace
France’s Sanofi to buy U.S. biopharma group Blueprint for up to $9.5-billion - The Globe and Mail
Sanofi doubles down on immunology with $9.1bn Blueprint deal - Proactive financial news
European ADR Index Slips As Pharma Stocks Buck The Trend - Finimize
Regeneron and Sanofi: Disappointing Top-Line Results for Itepekimab From Two Phase 3 Trials - Morningstar
Regeneron Pharmaceuticals Crashes 19% On A Surprise Sanofi-Tied Failure - Investor's Business Daily
Market movers: Canopy Growth, Zscaler, Regeneron... - Proactive financial news
Regeneron shares plunge after mixed COPD drug trial results - Proactive financial news
Penicillin Market Research Report 2025 - GlobeNewswire Inc.
Prurigo Nodularis Market - GlobeNewswire Inc.
8MM Bronchiectasis Market Opportunity Assessment and Forecasts, 2033 - GlobeNewswire Inc.
Dollar Stock Biotech Triples On $470 Million Sanofi Takeover - Investor's Business Daily
Metric Deep Dive: Understanding Sanofi ADR (SNY) Through its Ratios - DWinneX
iRhythm Technologies Inc (IRTC) Stock: Navigating Market Highs and Lows in 52 Weeks - investchronicle.com
WLK’s Stock Market Puzzle: Piecing Together 2023’s Performance - investchronicle.com
BIDU’s Stock Market Pendulum: Swinging Between Gains and Losses - investchronicle.com
A Tale of Resilience: Sanofi ADR Amid Stock Market Turbulence - investchronicle.com
Company’s Banking Stock: Dissecting a 40.08% Quarterly Revenue Decline Amid Growth - investchronicle.com
Trip.com Group Ltd ADR (TCOM) Stock: A Year of Stock Market Ups and Downs - investchronicle.com
CYTK’s 2023 Market Dance: Down -21.41% – Time to Invest? - investchronicle.com
CIG’s Market Whiplash: 8.19% YTD Rise, 9.30% Rise in 30 Days - investchronicle.com
Can Navitas Semiconductor Corp Bounce Back? 52-Week Performance and Analyst Predictions - investchronicle.com
LX’s 2023 Market Dance: Up 43.28% – Time to Invest? - investchronicle.com
Terex Corp (TEX) Stock: 52-Week Performance Insights and Trading Volume - investchronicle.com
Behind Cytosorbents Corp’s 52-Week Range: Uncovering Opportunities for Investors - investchronicle.com
Procore Technologies Inc (PCOR) Stock: A 52-Week Tale of Drops and Gains - investchronicle.com
Navigating TREE Stock: LendingTree Inc Journey - investchronicle.com
Companhia Siderurgica Nacional ADR (SID) Stock: From Low to High in 52 Weeks - investchronicle.com
The Future of EVgo Inc: Analyzing EVGO - investchronicle.com
Analyzing the Impact of Earnings Reports on Sunstone Hotel Investors Inc Inc. (SHO) Price Performance - investchronicle.com
NVS’s Stock Market Odyssey: A Year of Growth, Decline, and Resilience - investchronicle.com
Unilever plc ADR: Rising -3.90% from 52-Week Low, Can the Stock Stay Afloat? - investchronicle.com
TTWO’s Stock Market Pendulum: Swinging Between Gains and Losses - investchronicle.com
Futu Holdings Ltd ADR (FUTU) Stock: Navigating Market Highs and Lows in 52 Weeks - investchronicle.com
Stryker Corp (SYK) Stock: Navigating a Year of Volatility - investchronicle.com
Viking Holdings Ltd’s Banking’s 100-Day Moving Average at 44.43: Will the Stock Break Through? - investchronicle.com
CTRE’s Market Whiplash: 5.78% YTD Rise, 0.22% Rise in 30 Days - investchronicle.com
Sandisk Corp (SNDK) Stock: Navigating Market Highs and Lows in 52 Weeks - investchronicle.com
LSCC: Riding the Market Waves of Growth and Decline in 2023 - investchronicle.com
Canadian National Railway Co: Navigating Market Fluctuations with a 62.62B Market Cap - investchronicle.com
Finanzdaten der Sanofi Adr-Aktie (SNY)
Umsatz
Nettogewinn
Free Cashflow
ENV
0.18%
In Yahoo öffnen
|
In Google öffnen
|
In Finviz öffnen
|
In MarketWatch öffnen
|
Öffnen Sie in EDGAR
|
Offen in Reuters
Kapitalisierung:
|
Volumen (24h):